DREADDs: novel tools for drug discovery and development.

Autor: Lee HM; Department of Pharmacology, Program in Neuroscience, Division of Chemical Biology and Medicinal Chemistry, and NIMH Psychoactive Drug Screening Program, University of North Carolina, Chapel Hill Medical School, 4072 Genetic Medicine Building, Chapel Hill, NC 27514, USA., Giguere PM; Department of Pharmacology, Program in Neuroscience, Division of Chemical Biology and Medicinal Chemistry, and NIMH Psychoactive Drug Screening Program, University of North Carolina, Chapel Hill Medical School, 4072 Genetic Medicine Building, Chapel Hill, NC 27514, USA., Roth BL; Department of Pharmacology, Program in Neuroscience, Division of Chemical Biology and Medicinal Chemistry, and NIMH Psychoactive Drug Screening Program, University of North Carolina, Chapel Hill Medical School, 4072 Genetic Medicine Building, Chapel Hill, NC 27514, USA. Electronic address: bryan_roth@med.unc.edu.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2014 Apr; Vol. 19 (4), pp. 469-73. Date of Electronic Publication: 2013 Nov 01.
DOI: 10.1016/j.drudis.2013.10.018
Abstrakt: Since the invention of the first designer receptors exclusively activated by designer drugs (DREADDs), these engineered G protein-coupled receptors (GPCRs) have been widely applied in investigations of biological processes and behaviors. DREADD technology has emerged as a powerful tool with great potential for drug discovery and development. DREADDs can facilitate the identification of druggable targets and enable researchers to explore the activities of novel drugs against both known and orphan GPCRs. Here, we discuss how DREADDs can be used as novel tools for drug discovery and development.
(Copyright © 2013 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: